Correlation between Angiotensin Inhibitor Administration and Longer Survival in Patients Who Underwent Curative Resection for Pancreatic Cancer

Purpose:The microenvironment of pancreatic ductal adenocarcinoma (PDAC) with extensive desmoplastic stroma contributes to aggressive cancer behavior.Angiotensin system inhibitors (ASIs) reduce stromal fibrosis and are a promising therapeutic strategy.The purpose of this study was to examine how ASIs affected the oncological results of patients who had their PDAC removed.Materials and Methods: A retrospective assessment was conducted on the clinicopathological and survival data of patients who received curative resection for PDAC at Severance Hospital between January 2012 and December 2019.Results: A total of 410 participants (228 male and 182 female), with a median follow-up period of 12.8 months, were included in this study.Patients were divided into three groups, based on ASI use and history of hypertension: group 1, normotensive and never used ASI (n=210, 51.2%); group 2, ASI non-users with hypertension (n=50, 12.2%); and group 3, ASI users with hypertension (n=150, 36.6%).The three groups did not differ significantly in terms of age, sex, kind of operation, T and N stages, or adjuvant and neoadjuvant therapy.Moreover, there was no discernible difference in disease-free survival between those who used ASI and those who did not (p=0.636).The 5-year overall survival (OS) rates in groups 1, 2, and 3 were 52.6%, 32.3%, and 38.0%, respectively.However, the OS rate of ASI users was remarkably higher than that of non-users (p=0.016). Conclusion:In patients with resected PDAC, ASI is linked to longer survival rates.Furthermore, for individuals with hypertension, ASI in conjunction with conventional chemotherapy may be an easy and successful treatment option.